Global Health Watch: Congress signals support for global health + research, US loses measles elimination status, NIAID new director

Issue 95

November 20, 2026

Signs of Congressional pushback against the US Administration’s health and science agenda emerged this week as new funding bills were introduced, while nominations to lead the US FDA and National Science Foundation were rescinded. Meanwhile, the US lost its measles elimination status, and NIAID appointed a new director.

Congress Signals Support for Global Health and Research Amid Funding Uncertainty

The soon-to-be outgoing Chair of the Senate Appropriations Committee, Susan Collins (R-ME), released the Senate’s fiscal year 2027 (FY27) bills this week. The proposals include funding for global health programs and research within the State, Foreign Operations and Related Programs (SFOPS) (bill and report) and Labor, Health and Human Services, Education, and Related Agencies (LHHS) (bill and report). Analysis of these bills indicates continued support of the US Senate for global health programs and scientific research—and the power of advocacy in ensuring US members of Congress are aware of the issues and what’s at stake. Overall, the Senate proposals would maintain or modestly increase funding for key global health R&D and women’s health innovation efforts as compared with FY26 and the significant cuts proposed in the Administration’s FY27 budget request. The House versions of the Bills provide lower funding levels overall than the Senate, but both chambers of Congress are well above the President’s request. 

Also, this week, the US Supreme Court declined to hear an appeal challenging lower-court rulings involving the Administration’s termination of federal research grants over diversity, equity and inclusion. As Nature reports, this decision leaves in place rulings protecting affected grants while litigation continues. 

IMPLICATIONS: The release of these bills by Sen. Collins lays down a marker on funding and policy priorities, just as the continuing resolution (CR) for the budget is set to expire on December 11. There is, therefore, little time for lawmakers in this current Congress to negotiate a deal on FY27 funding. Congress will turnover on January 3, 2027, with an influx of new members and leadership changes across committees. Of particular concern in the FY27 bills is the absence of a provision that blocks OMB from conducting politically-biased grant reviews, which was a key feature in the current continuing resolution that will expire next month. Democrats are expected to signal pushing negotiations into next year by extending the current continuing resolution to give more time for lawmakers to negotiate and resolve polarizing issues.   

These developments highlight the growing tension between Congressional funding priorities, the Administration’s efforts to reduce and reshape federal support for global health and scientific research, and judicial oversight of it all. While the Senate proposals indicate support for global health programs facing significant funding uncertainty, they are not yet law, and Congressional appropriations alone do not guarantee that funds will be released or programs sustained. Over the past 22 months, restrictions and delays in the Administration’s spending of appropriated funds have been well documented, raising concerns about whether funding is being used in accordance with congressional intent. The Supreme Court’s decision provides a limited legal check on certain grant terminations but does not establish broad protections against future cuts. For HIV and global health research, there is still much uncertainty around whether Congress will sustain funding, whether appropriated resources will reach programs and researchers, and whether we will continue to see disruption in research and essential services. 

READ:

Two Federal Agency Nomination Setbacks

In less than 24 hours, two of the Administration’s nominees to lead major federal science and health agencies faced significant setbacks. The Administration withdrew its nomination of Heidi Overton to lead the US Food and Drug Administration (FDA), likely because she lacked support from US Senators. Overton faced criticism over her positions on vaccines, abortion and reproductive health and her refusal to directly answer questions during her September confirmation hearing. The Senate Health, Education, Labor and Pensions (HELP) Committee also canceled a scheduled vote on Jim O’Neill’s nomination to lead the National Science Foundation (NSF). Committee Chair Senator Bill Cassidy (R-LA) said O’Neill failed to adequately defend science against decisions and statements by Health Secretary Robert F. Kennedy Jr., specifically citing his role in the dismissal of former CDC Director Susan Monarez.  

IMPLICATIONS: The withdrawal of Overton’s nomination and stalled consideration of O’Neill leave the FDA and NSF without confirmed leaders. It is unlikely the current Senate will have time to advance new nominees before the next Congress, controlled by Democrats, convenes in January 2027. These developments may also signal a broader shift in congressional willingness to challenge the Administration when it comes to public health and science. After years of disruptions to scientific research, public health institutions and evidence-based policymaking, some members of Congress appear more willing to question decisions they previously supported or declined to challenge. Sustained advocacy by scientists, public health experts and communities has helped keep these issues in the public and political spotlight, creating opportunities for greater congressional scrutiny and accountability. Whether this represents a lasting course correction remains to be seen, but it underscores the importance of continued advocacy to protect scientific independence and public health. 

READ:

New NIAID Director Appointed Amid Much Uncertainty

John H. Powers III was appointed director of the National Institute of Allergy and Infectious Diseases (NIAID) this week, after previously serving as acting director. Powers is an infectious disease physician and clinical trialist. More recently, he gained influence within this US Administration through his interest in research on vaccine-related injuries. His appointment follows the dismissal of former director Jeanne Marrazzo and the subsequent replacement of acting director Jeffery Taubenberger.

IMPLICATIONS: Powers assumes leadership of NIAID at a critical moment for HIV and infectious disease research. NIAID faces unresolved questions about its proposed reorganization, which would eliminate the Division of Clinical Research and redistribute oversight of clinical research. It also faces continuing delays in funding opportunities for the next funding cycle of the four HIV Clinical Trials Networks. In September, AVAC submitted comments raising concerns about disruptions to research infrastructure, trial oversight and meaningful community engagement, and urging NIH to withdraw the reorganization proposal and release delayed funding opportunities. In October, AVAC joined with colleagues in the Save HIV Funding campaign calling for congressional intervention. With some new studies already delayed, Powers’ leadership will be closely watched for decisions that could shape the future of HIV research, the stability of global clinical trial networks and the role of communities in setting research priorities. 

READ:

US Loses Measles Elimination Status

The United States has officially lost its measles elimination status, which was confirmed by the Pan American Health Organization (PAHO) Tuesday. The US joins Canada, Mexico and Bolivia in losing its status and marks a monumental reversal of decades of public health progress. Regaining the designation of measles elimination will require 12+ months without continuous transmission, along with strong disease surveillance and outbreak response systems. Many public health experts warn that this could take years as measles and vaccine disinformation continue to circulate. Inside Medicine reports that some Democratic members of the US Congress are calling for an investigation into CDC Director Erica Schwartz’s handling of the outbreaks when the new Congress convenes in January, citing inadequate responses to congressional questions and concerns about the agency’s reporting and response. 

IMPLICATIONS: The loss of elimination status underscores the consequences of declining vaccination coverage, gaps in disease surveillance and weakened public health infrastructure. It also shows just how quickly decades of scientific and public health progress can be reversed when trust in science erodes and misinformation and disinformation about interventions prevail. As we noted in last week’s issue, when government leaders amplify misinformation or undermine the credibility of scientific institutions, they jeopardize the foundation on which broader public health efforts depend.  

READ:

What We’re Reading

Resources